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ABSTRACT 
Background: The aims of this study were to describe the prevalence of QRS prolongation and 
abnormal QRS morphology in patients with heart failure and preserved ejection fraction (HF-PEF) 
and to examine the relationship between these QRS abnormalities and clinical outcomes.  
 
Methods: We categorized patients in the Irbesartan in Patients with Heart Failure and Preserved 
Ejection Fraction trial (I-Preserve) according to QRS duration <120 vs. e120 milliseconds and QRS 
morphology: normal, left bundle branch block (LBBB) and right bundle branch block (RBBB) or 
other non-specific intra-ventricular conduction defect (IVCD). The outcomes examined were the 
composite of cardiovascular death or heart failure hospitalization (and its components) and all-
cause mortality.  
 
Results: Of the 4128 patients enrolled in I-Preserve, 3754 were included in the current analyses.  
606 patients had a QRS duration e120 milliseconds. 302 had LBBB and 742 had RBBB/IVCD. 
Patients with an abnormal QRS had evidence of more severe heart failure (lower LVEF, lower 
eGFR, higher NT pro-BNP) and worse clinical status (higher NYHA functional class, greater use of 
diuretics). Both abnormalities of QRS duration and QRS morphology were associated with worse 
outcomes.  The rates of the composite outcome were: 6.0 and 9.3 per 100 patient years in the <120 
and e120 millisecond groups, respectively (adjusted hazard ratio [HR] 1.32, 1.11-1.57; P=0.002) 
and 6.0, 7.7 and 8.7 per 100 patient years in the normal, non-LBBB and LBBB groups respectively 
(adjusted HR 1.19, 1.00-1.42; P=0.046 and 1.31, 1.03-1.66; P=0.026, respectively, compared with 
normal). The heightened risk related to QRS abnormalities persisted after adjustment for other 
prognostic variables, including NT pro-BNP. 
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Conclusion: We found that both prolongation of QRS duration and abnormal QRS morphology 
were associated with a high risk of fatal and non-fatal adverse outcomes in HF-PEF. 
Key words:  Clinical trial, Heart failure, Preserved ejection fraction, Irbesartan 
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INTRODUCTION 
The prognostic importance of QRS duration and morphology on the 12 lead electrocardiogram 
(ECG) in patients with heart failure and reduced ejection fraction (HF-REF) is well recognised.1-4  
Prolonged QRS duration and bundle branch block (BBB) are surface markers of dys-synchronous 
left ventricular contraction which is associated with worse outcomes in patients with HF-REF. 1-4  
As such, these ECG parameters are used to identify patients who may benefit from cardiac 
resynchronization therapy.5,6 
 
However, little is known about the prognostic importance of QRS duration and morphology in 
patients with chronic heart failure and preserved ejection fraction (HF-PEF).7,8  Whether prolonged 
QRS duration and/or BBB is associated with worse heart failure outcomes in these patients has not 
been determined although, recently, left ventricular systolic dys-synchrony has also been 
demonstrated in HF-PEF patients, particularly in those with a wide QRS duration.9  The aims of 
this study were to describe the prevalence of QRS prolongation and abnormal QRS morphology 
and examine the relationship between these QRS abnormalities and fatal and non-fatal heart failure 
outcomes in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial.10  
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METHODS 
The design, baseline characteristics and results of I-Preserve are published.10,11 Briefly, 4128 
patients aged e  60 years with a left ventricular ejection fraction (LVEF) e  45%, current signs and 
symptoms of heart failure and corroborating evidence (relevant electrocardiographic, chest X-ray or 
echocardiographic abnormalities) were randomized to 300mg once daily of irbesartan or placebo. 
Patients in New York Heart Association (NYHA) functional classes II to IV were eligible but those 
in class II were required to have had a hospitalization for heart failure within the previous 6 months. 
Ethics committees at each participating institute approved the trial and all patients provided written 
informed consent. The mean follow-up was of 49.5 months.  No significant difference was seen in 
the primary composite outcome of death from any cause or hospitalization for a CV cause, or in any 
of the pre-specified secondary endpoints.  
 
QRS duration and morphology: Investigators were asked to provide a report of the patient’s ECG 
at the trial-screening visit using a structured case report form.  This form asked about the QRS 
width (reported in milliseconds) and whether the patient had LBBB or RBBB or another intra-
ventricular conduction defect (check box).  We used this information to divide the patients into two 
QRS duration categories (<120 and e  120 milliseconds) and three QRS morphology categories: no 
BBB, LBBB, RBBB or “other non-specific intra-ventricular conduction defect” (IVCD).  The latter 
QRS morphology category was created by adding together patients with a checkbox completed for 
IVCD and patients with a QRS duration e  120 milliseconds but neither LBBB nor RBBB reported 
on the case report form.  Patients with a pacemaker (conventional or a resynchronization device) 
were excluded in the present analysis, as were patients with implausible QRS widths (<60 and >220 
milliseconds). 
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Clinical outcomes: The clinical outcomes of interest in this analysis were the composite outcome 
of cardiovascular death or heart failure hospitalization and its components, as these are thought to 
best reflect disease-specific outcomes. 
 
Statistical analyses: Baseline characteristics were summarized as mean with standard deviation for 
continuous variables and numbers with percentages for categorical variables. Baseline 
characteristics were compared between the QRS duration categories using student’s t test for 
continuous variables and the chi-square test for categorical variables. Baseline characteristics across 
QRS morphology categories were compared using ANOVA for continuous variables and chi-
square test for categorical variables. Duration of heart failure, Minnesota living with heart failure 
questionnaire (MLHFQ) scores and N-terminal pro B-type natriuretic peptide (NT pro-BNP) were 
not normally distributed and therefore were summarized as medians and interquartile ranges and 
analyzed using the Mann-Whitney U test or Kruskal-Wallis test. Event rates for each of the 
outcomes of interest in each of the QRS duration and morphology categories were calculated per 
100 patient years of follow-up and also illustrated using Kaplan-Meier curves and compared with 
the log rank test. The hazard ratios (HR) were calculated using Cox proportional hazard models 
adjusting for the prognostic variables identified to be most predictive of outcomes, as previously 
reported.12 These variables included age, left ventricular ejection fraction, heart rate, ischemic 
aetiology, diabetes mellitus, myocardial infarction, hospitalization for heart failure in the past 6 
months, history of chronic obstructive pulmonary disease or asthma, neutrophil count, estimated 
glomerular filtration rate, and NT pro-BNP. 12 A total of 663 patients with missing data (mainly NT 
pro-BNP) were excluded from the multivariable analyses. All P-values are two-sided and a value of 
<0.05 was considered significant. All statistical analyses were performed using Stata version 12 
(Stata Corp, College Station, TX, USA). A variety of sensitivity analyses were conducted including 
examination of different QRS duration categories (QRS duration dichotomized at 130 milliseconds; 
QRS duration categories <120, 120-149, e150 milliseconds), different QRS morphologies (RBBB, 
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LBBB and IVCD separately), and QRS duration as a continuous variable. QRS duration and 
morphology were also added simultaneously to the multivariable model and we tested for a possible 
interaction between QRS duration/morphology and atrial fibrillation at baseline. 
 
RESULTS 
A total of 4128 patients were randomized in I-Preserve.  Of these, 252 had a pacemaker and were 
therefore excluded from analysis. A further 11 patients had a missing QRS duration or a QRS 
duration that was implausibly low (n=92) or high (n=19), leaving 3754 patients for analysis.  
Overall, QRS duration was <120 milliseconds in 3148 patients (84%) and e  120 milliseconds in 
606 patients (16%).  Of all analysable patients, investigators identified 302 (8.0%) as having 
LBBB, 261 (7.0%) with RBBB and 481 (12.8%) with non-specific intra-ventricular conduction 
defect (IVCD) i.e. 742 (19.8%) had non-LBBB QRS abnormalities. Seventy two percent of 
analysable patients (2710) had no abnormality of QRS configuration.  The mean (standard 
deviation) QRS duration was 135 (25), 112 (27) and 86 (12) milliseconds in the LBBB, 
RBBB/IVCD and normal QRS morphology groups, respectively.  Of the 606 patients with a QRS 
duration e  120 milliseconds, 249 (41.1%) had LBBB, 192 (31.7%) had RBBB and 165 (27.2%) had 
non-specific IVCD. 
 
Baseline characteristics 
Table 1a shows the baseline characteristics of patients according to QRS duration category and 
Table 1b according to QRS morphology category.   
 
QRS duration: Compared to those with a QRS duration <120 milliseconds, patients with a longer 
QRS duration were slightly older on average, more commonly male, were more likely to have a 
history of myocardial infarction and had a lower mean left ventricular ejection fraction.  Longer 
QRS duration was also associated with worse renal function and a higher mean NT pro-BNP level.  
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When compared to a QRS duration <120 milliseconds, those with a longer QRS duration were 
more likely to display certain adverse clinical signs such as ventricular gallop (S3) and jugular 
venous distension. Patients with a QRS duration e120 milliseconds were less likely than those with 
a narrower QRS duration to have peripheral oedema but were more likely to be treated with a loop 
diuretic therapy and less likely to be treated with a calcium channel blocker. Baseline 
characteristics for patients dichotomized at a QRS duration of 130 milliseconds and categorized 
into three groups according to QRS duration <120, 120-149 and e150 milliseconds are shown in the 
Supplementary Appendix (Tables 1-5). 
 
QRS morphology: Compared to those with a normal QRS morphology, patients with abnormal QRS 
morphology showed similar patterns to those described above for patients with a QRS duration e 
120 milliseconds and some additional differences including longer duration of heart failure and 
worse NYHA functional class. Those with abnormal QRS morphology had higher (worse) 
Minnesota Living With Heart Failure Questionnaire scores and generally, patients with LBBB had 
more manifestations of severe heart failure than those with RBBB/IVCD e.g. lower LVEF, worse 
NYHA class, higher NT pro-BNP, lower haemoglobin and worse renal function and greater diuretic 
use but did not have longer duration of heart failure or more frequent recent hospitalization for 
heart failure (although we cannot account for survivor bias). Baseline characteristics for patients 
categorized into four QRS morphology groups (normal, RBBB, LBBB and IVCD) are shown in the 
Supplementary Appendix (Tables 6 and 7). 
 
Clinical outcomes  
Rates of the composite outcome and its components (cardiovascular death and heart failure 
hospitalization), along with death from any cause are shown in Table 2.  As can be seen from Table 
2 (and Figures 1&2) both prolonged QRS duration and abnormal QRS morphology were associated 
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with a considerably higher risk of the composite outcome, compared with a QRS duration <120 
milliseconds and normal QRS morphology separately.   
 
QRS duration: In patients with a QRS duration <120 milliseconds, the rate of the composite 
outcome was 6.0 per 100 patient years of follow-up whereas in those with a prolonged QRS 
duration the rate was approximately 9.3 per 100 patient years of follow-up (Table 2).  On univariate 
analysis, the risk of the composite outcome was 50% higher among patients with a prolonged QRS 
duration and the hazard was only slightly attenuated (to 32% higher) after adjustment in the 
multivariable model including NT pro-BNP (and this did not change significantly after further 
adjustment for male sex and baseline treatment with a loop diuretic). A similar pattern was seen for 
both components of the composite although the hazard ratio for cardiovascular death was higher 
than for heart failure hospitalization. Longer QRS duration was associated with a higher risk of the 
two main modes of cardiovascular death i.e. sudden death and pump failure death and the elevation 
in risk of each type of death was proportionately similar.  The risk of death from any cause was also 
higher in patients with a QRS duration e  120 milliseconds compared to those with a QRS duration 
<120 milliseconds (Table 2). Qualitatively similar findings were seen dichotomizing QRS duration 
at 130 milliseconds (Supplementary Appendix Table 2; Figures 1-4). The elevated risk associated 
with longer QRS duration was not greater in patients with a QRS duration e150 milliseconds 
compared with a duration of 120-149 milliseconds (Supplementary Appendix Table 4; Figures 5-8). 
When QRS duration was examined as a continuous variable, a linear relationship was observed for 
cardiovascular (and all-cause) death up to a QRS duration of approximately 130 milliseconds 
(Supplementary Appendix Table 5). 
 
QRS morphology: In patients with normal QRS morphology, the rate of the primary composite 
outcome was 6.0 per 100 patient years of follow-up whereas in those with RBBB/IVCD it was 7.7 
per 100 patient years of follow-up and in individuals with LBBB it was 8.7 per 100 patient years of 
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follow-up (Table 2).  On univariate analysis, the risk of the composite outcome was 30% higher 
among patients with RBBB/IVCD and 40% higher among those with LBBB.  The hazard was 
somewhat attenuated after adjustment in the multivariable model - to 19% and 31%, respectively 
(and this did not change significantly after further adjustment for male sex and baseline treatment 
with a loop diuretic). A similar pattern was seen for both components of the composite although the 
hazard ratio for cardiovascular death was higher than for heart failure hospitalization for both types 
of conduction disturbance. The hazard ratios for the composite and both its components were also 
higher in the LBBB group compared with the non-LBBB group. Similarly the risk of the two main 
modes of cardiovascular death was elevated more in patients with LBBB than in the non-LBBB 
group (but the elevation in risk of each type of death was proportionately similar).  The risk of 
death from any cause was also higher in patients with an abnormal QRS morphology and higher in 
those with LBBB compared with RBBB/IVCD (Table 2). When patients were categorized into four 
QRS morphology groups, the adjusted hazard ratios, compared with a normal QRS, were 
numerically (but not statistically significantly) less elevated in the RBBB group than in the LBBB 
and IVCD groups (Supplementary Appendix Table 7; Figures 9-12). 
 
QRS duration and morphology considered simultaneously: We also entered both QRS duration and 
QRS morphology into the multivariable model simultaneously. For the outcome of cardiovascular 
death, QRS morphology did not substantially diminish the predictive value of QRS duration 
(examined as a continuous variable) whereas simultaneous entry of QRS duration (continuous) 
largely eliminated the predictive value of QRS morphology for cardiovascular (and all-cause) 
mortality. The superior predictive value of QRS duration over QRS morphology, when both 
variables were modelled simultaneously, was not as clear for heart failure hospitalization 
(Supplementary Appendix Tables 8 and 9).  
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We found no interaction between QRS duration or QRS morphology and atrial fibrillation at 
baseline. 
 
DISCUSSION 
The main findings in this study were that among the HF-PEF patients enrolled in I-Preserve those 
with a prolonged QRS duration or BBB experienced a considerably higher risk of the composite 
outcome of cardiovascular death or heart failure hospitalization (particularly cardiovascular death), 
compared to patients without such ECG abnormalities.  
 
A prolonged QRS duration is found in 24 to 47% of patients with HF-REF and is believed to be a 
surface marker of left ventricular mechanical dys-synchrony.13-17 Patients with HF-REF and QRS 
prolongation, especially if associated with a LBBB pattern, have a guideline indication for cardiac 
resynchronization therapy.5,6 Few studies however, have examined the prevalence of QRS 
prolongation or described QRS morphology in patients with chronic HF-PEF and fewer still have 
examined their impact on clinical outcomes. 
 
We found that 16% of patients in I-Preserve had prolonged QRS duration. The only other sizeable 
study to describe the prevalence of ECG abnormalities in ambulatory patients with HF-PEF was the 
Swedish Heart Failure Registry which enrolled over 57 000 individuals between May 2000 and 
March 2011.8  Of those with a preserved left ventricular ejection fraction (e  50%), a very similar 
proportion, 18%, had a prolonged QRS duration. However, this was a much lower proportion than 
in patients with HF-REF i.e. 39% of patients with an ejection fraction <40%.   
 
We found that nearly 20% of patients in I-Preserve were reported to have RBBB/IVCD (7% RBBB 
and 13% IVCD) and an additional 8% had LBBB morphology. We are not aware of any prior 
report about the specific type of QRS configuration in a large cohort of ambulatory patients with 
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HF-PEF. However, in the CHARM Programme, 14.4% with HF-PEF had undifferentiated BBB, 
compared with 30.1% of those with HF-REF.15 Other large studies in patients with HF-REF have 
also described a much larger proportion of patients with BBB compared with the proportion in I-
Preserve. Additionally, those other studies describe a greater fraction of patients with LBBB and a 
smaller proportion with RBBB/IVCD. For example, the prevalence of LBBB was 25% in the large 
Italian Network on Congestive Heart Failure Registry, compared with the 8% we found in I-
Preserve whereas the proportion of patients with RBBB/IVCD was 12% compared with 20% in I-
Preserve.10  
 
The prevalence of a wide QRS complex in I-Preserve was much higher than in the general 
population.  For example, among close to 15,000 individuals without known coronary heart disease 
(CHD) in the Atherosclerosis Risk in Communities study ARIC, only 456 (3.1%) had a QRS 
duration e120ms.18  Among 1759 subjects without CHD or heart failure in the Framingham Heart 
Study, 113 (6.4%) had a QRS duration e120ms. 19  In I-Preserve, this proportion was 16% - not 
nearly as common as in HF-REF but much more than in the general population, presumably 
reflecting greater co-morbidity and myocardial damage in the patients in I-Preserve. 20 We found 
that previous myocardial infarction and longer duration heart failure, both of which are likely to 
lead to myocardial fibrosis, were associated with QRS abnormalities. However, neither 
hypertension nor diabetes, which might also be expected to have similar pathophysiological effects, 
were more common in patients with QRS abnormalities. Other pathophysiological abnormalities 
such as microvascular disease and vascular rarefaction might also lead to myocardial ischaemia, 
necrosis and fibrosis.21 
 
 
As mentioned earlier, QRS prolongation and BBB morphology are surface markers of left 
ventricular mechanical dys-synchrony in patients with HF-REF. A recent analysis of 130 HF-PEF 
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patients in the Prospective comparison of ARNI (Angiotensin receptor neprilysin inhibitor) with 
ARB (Angiotensin receptor blocker) on management of heart failure with preserved ejection 
fraction trial (PARAMOUNT) found that 13% had evidence of mechanical dys-synchrony on 2D 
speckle tracking echocardiographic analysis, and this correlated with QRS prolongation on the 
surface ECG.9 It is therefore possible that the substantial minority of patients with QRS 
abnormalities in I-Preserve had underlying mechanical dys-synchrony. Certainly, the I-Preserve 
patients with abnormal QRS duration and morphology had evidence of more severe heart failure 
(lower LVEF, lower eGFR, higher NT proBNP) and worse clinical status (higher NYHA functional 
class, greater use of diuretics), consistent with the clinical picture in patients with HF-REF and 
QRS abnormalities. 
 
We found that abnormal QRS duration and morphology were associated with worse clinical 
outcomes in patients with HF-PEF, including higher rates of death (cardiovascular death in 
particular) and hospitalization for worsening heart failure. This association with higher mortality 
and to a lesser extent, heart failure hospitalization, persisted after extensive adjustment for other 
prognostic variables, including NT pro-BNP. This finding is consistent with prior studies in HF-
REF. We know of only one other large study examining outcomes according to QRS duration in 
ambulatory patients with HF-PEF. In the Swedish Heart Failure Registry, QRS prolongation was 
related to higher all-cause mortality although this association was stronger in patients with a lower 
LVEF.8 We found that the association between QRS duration and cardiovascular mortality was 
stronger than for all-cause mortality in I-Preserve, probably because QRS abnormalities are not 
predictive of non-cardiovascular death and non-cardiovascular causes of death are relatively 
common in patients with HF-PEF, compared with HF-REF. Heart failure hospitalization was not 
reported in the Swedish Registry study but we found that QRS prolongation is also a predictor of 
this non-fatal outcome in HF-PEF although not as strong a predictor as for cardiovascular death.  
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We also showed that abnormal QRS morphology is associated with worse outcomes and that LBBB 
appeared to carry a greater risk than RBBB/IVCD. These findings contrast with those of the 
CHARM Programme where undifferentiated BBB was associated with significantly worse 
outcomes in HF-PEF in univariate analyses but not in the multivariable analyses. This difference 
may reflect the relatively small number of patients with BBB in CHARM-Preserved (n=434).15  
 
When we examined the predictive value of QRS duration and morphology simultaneously, only 
QRS duration was predictive of cardiovascular (and all-cause) death. This observation is of interest 
given the recent meta-analysis demonstrating that the benefit of cardiac resynchronization therapy 
(CRT) in HF-REF was predicted by QRS duration more than QRS morphology (QRS morphology 
did not add any predictive information over and above QRS duration examined as a continuous 
variable). This meta-analysis also demonstrated that CRT was most clearly of benefit in patients 
with a QRS duration e130 milliseconds.22   
 
Although the elevated risk associated with abnormal QRS duration or morphology was modest 
(with the highest adjusted hazard ratio for the primary composite outcome of 1.32 for a QRS 
duration of e120ms), this is a larger increment in risk than associated with a 5 year increase in age 
or prior myocardial infarction and similar to that related to diabetes. 
 
As with any analysis of this type there are limitations. It was not prospectively planned i.e. was 
retrospective. This, plus the examination of 5 subgroups and 4 endpoints increases the risk of 
chance findings. Original ECGs were not available and this analysis was based on information 
provided by investigators on study case report forms.  
 
In summary, we found that HF-PEF patients with prolonged QRS duration or BBB experienced a 
considerably higher risk of the primary composite outcome of cardiovascular death or heart failure 
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hospitalization, compared to patients without these ECG abnormalities.  Despite advances in 
technology, the ECG remains an accessible tool for identifying heart failure patients with 
ventricular conduction delay who are at high cardiovascular risk, regardless of whether they have 
reduced or preserved ejection fraction. 
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CLINICAL PERSPECTIVES 
 
Our findings have a number of clinical implications. Firstly, it seems clear that QRS abnormalities 
are independent and important prognostic variables in HF-PEF - which may be useful in risk 
stratification clinically and in decisions about intensity of patient surveillance and follow-up. As 
little is known about the incidence of QRS prolongation/BBB in HF-PEF, future studies may also 
look at the development of new QRS abnormalities and the significance of this. QRS abnormalities 
may also provide a means of selecting higher-risk patients for clinical trials. Lastly, and more 
controversially, the current findings also raise the possibility that cardiac resynchronization therapy 
might have a therapeutic role in HF-PEF, as in HF-REF.7, 17, 22,23  CRT has been shown to be 
ineffective or even harmful in patients with HF-REF who do not have “electrical dys-synchrony” 
(i.e. an abnormal) QRS as opposed to mechanical dys-synchrony.24   This intervention however, has 
recently been tested in a small trial involving 24 participants with HF-PEF, normal QRS duration 
on electrocardiography and features of mechanical dys-synchrony on echocardiography.  The 
results showed signs of improved ventricular relaxation accompanied by a small but significant 
improvement in diastolic and systolic haemodynamics at longer atrio-ventricular pacing intervals 
during biventricular, or isolated left ventricular pacing.25 It is therefore possible that CRT might be 
beneficial in patients with interventricular dys-synchrony as demonstrated by QRS prolongation.7 
Clearly, however, this hypothesis would need to be tested in a randomized clinical trial. 
Identification of HF-PEF patients potentially suitable for device therapy might be one approach to 
targeting treatment to a particular HF-PEF phenotype. We recently published a study using latent 
class analysis to try and identify specific HF-PEF phenotypes in I-Preserve and validated this 
approach in CHARM-Preserved. Unfortunately, because CHARM did not collect information on 
QRS duration and morphology, QRS variables were not included in the latent class analysis.26 
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Table legends 
Table 1a. Baseline Characteristics according to QRS duration 
Table 1b. Baseline Characteristics according to QRS morphology category 
Table 2. Endpoints according to QRS duration and morphology category  
 
Figure legends 
Figure 1: Cardiovascular death or hospitalization for HF according to QRS duration 
 
Figure 2: Cardiovascular death or hospitalization for HF according to QRS morphology
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Table 1a. Baseline Characteristics according to QRS duration 
 QRS duration - msec  
Characteristic 
<120 
(N=3148) 
e120 
(N=606) p-value 
Age - year 71.2 ± 6.8 72.5 ± 6.9 <0.0001 
Male sex - no.(%) 1174 (37.3) 302 (49.8) <0.0001 
Race - no.(%)   0.53 
White 2947 (93.6) 575 (94.9)  
Black 65 (2.1) 11 (1.8)  
Asian-Pacific 17 (0.5) 4 (0.7)  
Other 119 (3.8) 16 (2.6)  
Body-mass index 29.7 ± 5.2 29.7 ± 5.5 0.93 
Heart rate - beats/min 71.5 ± 10.6 71.3 ± 10.3 0.61 
Blood Pressure - mmHg    
Systolic 136.6 ± 14.7 136.7 ± 15.1 0.90 
Diastolic 79.1 ± 8.9 78.5 ± 9.4 0.10 
Ejection fraction - % 59.7 ± 9.0 57.6 ± 9.1 <0.0001 
NYHA class - no.(%)   0.72 
II 661 (21.0) 130 (21.5)  
III 2404 (76.4) 456 (75.4)  
IV 82 (2.6) 19 (3.1)  
Etiology - no.(%)   0.29 
Ischemic 776 (24.7) 167 (27.6)  
Hypertension 2049 (65.1) 376 (62.0)  
Other 323 (10.3) 63 (10.4)  
Duration of heart failure - year   0.54 
Median 1.1 1.0  
Q1,Q3 [0.2, 3.3] [0.2, 3.6]  
Medical history - no.(%)    
Hospitalization for heart failure 
within previous 6 months 
1376 (43.7) 266 (43.9) 0.93 
Hypertension 2818 (89.5) 530 (87.5) 0.14 
Stable angina 1291 (41.0) 225 (37.1) 0.07 
Unstable angina 221 (7.0) 50 (8.3) 0.28 
Myocardial infarction 718 (22.8) 164 (27.1) 0.02 
PCI or CABG 382 (12.1) 88 (14.5) 0.10 
Atrial fibrillation 874 (27.8) 156 (25.7) 0.31 
Diabetes mellitus 842 (26.7) 169 (27.9) 0.56 
Stroke or transient ischemic attack 288 (9.1) 66 (10.9) 0.18 
COPD or asthma 274 (8.7) 64 (10.6) 0.14 
Left bundle-branch block 53 (1.7) 249 (41.1) <0.0001 
Right bundle-branch block 69 (2.2) 192 (31.7) <0.0001 
IVCD 320 (10.2) 83 (13.7) 0.01 
No BBB/IVCD 2710 (86.1) 0 (0.0)  <0.0001 
MLHFQ Score†   0.17 
Median 42.0 43.0  
Q1, Q3 [28.0, 59.0] [27.0, 56.0]  
Symptoms and signs  - no.(%)    
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Ventricular gallop (S3) 234 (7.4) 71 (11.7) 0.0004 
Jugular venous distention > 6 cm 248 (7.9) 63 (10.4) 0.04  
Lungs   0.97  
Basilar rales 777 (24.7) 151 (24.9)   
Diffuse rales 97 (3.1) 19 (3.1)   
wheeze 73 (2.3) 16 (2.6)   
Hepatomegaly 601 (19.1) 108 (17.9) 0.46  
Peripheral oedema   0.004 
none 1397 (44.4) 288 (47.5)   
trace 1024 (32.5) 162 (26.7)   
1+ to 2+ 671 (21.3) 136 (22.4)   
3+ to 4+ 54 (1.7) 20 (3.3)   
Medication - no.(%)    
Diuretic 2612 (83.1) 519 (85.6) 0.12 
Loop 1597 (50.8) 335 (55.3) 0.04 
Thiazide 1268 (40.3) 207 (34.2) 0.005 
Spironolactone 463 (14.7) 101 (16.7) 0.22 
ACE inhibitor 783 (24.9) 172 (28.4) 0.07 
Beta blocker 1897 (60.3) 340 (56.1) 0.05 
Calcium channel blocker 1282 (40.8) 221 (36.5) 0.05 
Digitalis 418 (13.3) 72 (11.9) 0.35 
Antiarrhythmic drug 259 (8.2) 54 (8.9) 0.58 
Aspirin 1748 (55.6) 345 (56.9) 0.54 
Antiplatelet 1861 (59.2) 375 (61.9) 0.21 
Antithrombotic 548 (17.4) 108 (17.8) 0.81 
Lipid-lowering agent 928 (29.5) 219 (36.1) 0.001 
Laboratory measurements    
Hemoglobin - g/dl 14.0 ± 1.5 14.1 ± 1.5 0.43 
Potassium - mmol/l 4.5 ± 0.5 4.5 ± 0.5 0.99 
Creatinine - mg/dl 0.98 ± 0.31 1.04 ± 0.33 <0.0001 
eGFR - ml/min/1.73 m2 73.5 ± 22.3 71.2 ± 22.5 0.02 
eGFR <60 ml/min/1.73 m2 - no.(%) 883 (28.7) 204 (34.4) 0.01 
Neutrophil -10^3 cells/ul 4.5 ± 1.8 4.5 ± 1.6 0.88 
NT-pro BNP - pg/ml   <0.0001 
Median 305.0 425.0  
Q1, Q3 [123.0, 855.0] [175.0, 1116.0]  
NYHA, New York heart association; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; ICD, 
implantable cardioverter defibrillator; COPD, chronic obstructive pulmonary disease; IVCD, intra-ventricular conduction defect ; 
BBB, bundle branch block; MLHFQ , Minnesota Living with Heart Failure Questionnaire; ACE, angiotensin converting enzyme; 
eGFR, estimated glomerular filtration rate; NT-pro BNP, N-terminal pro-B type natriuretic peptide.  
† Possible scores range from 0 to 105, with lower scores indicating a better quality of life. 
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Table 1b. Baseline Characteristics according to QRS morphology 
category 
   
  
QRS morphology 
Category 
  
Characteristic 
Normal non-LBBB LBBB 
p-value 
n=2710 n=742 n=302 
Age - year 71.1 ± 6.8 71.8 ± 6.8 72.6 ± 6.9 <0.001 
Male sex - no.(%) 987 (36.4) 375 (50.5) 114 (37.7) <0.0001 
Race - no.(%) 
   
0.35 
White 2534 (93.5) 699 (94.2) 289 (95.7) 
 
Black 60 (2.2) 12 (1.6) 4 (1.3) 
 
Asian-Pacific 12 (0.4) 7 (0.9) 2 (0.7) 
 
Other 104 (3.8) 24 (3.2) 7 (2.3) 
 
Body-mass index 29.7 ± 5.2 29.8 ± 5.5 29.1 ± 5.0 0.13 
Heart rate - beats/min 71.6 ± 10.6 70.5 ± 10.2 72.9 ± 10.6 0.002 
Blood Pressure - mmHg 
    
Systolic 136.4 ± 14.7 137.1 ± 14.8 137.3 ± 14.7 0.41 
Diastolic 78.9 ± 9.0 79.4 ± 9.1 78.9 ± 8.9 0.32 
Ejection fraction - % 59.9 ± 9.2 58.8 ± 8.7 56.0 ± 8.5 <0.0001 
NYHA class - no.(%) 
   
0.003 
II 580 (21.4) 164 (22.1) 47 (15.6) 
 
III 2068 (76.3) 554 (74.7) 238 (79.1) 
 
IV 61 (2.3) 24 (3.2) 16 (5.3) 
 
Etiology - no.(%) 
   
0.08 
Ischemic 661 (24.4) 202 (27.2) 80 (26.5) 
 
Hypertension 1763 (65.1) 479 (64.6) 183 (60.6) 
 
Other 286 (10.6) 61 (8.2) 39 (12.9) 
 
Duration of heart failure - year 
   
<0.0001 
Median 1.0 1.4 1.2 
 
Q1,Q3 [0.2, 3.2] [0.3, 3.6] [0.3, 3.9] 
 
Medical history - no.(%) 
    
Hospitalization for heart failure within 
previous 6 months 
1214 (44.8) 317 (42.7) 111 (36.8) 0.02 
Hypertension 2410 (88.9) 674 (90.8) 264 (87.4) 0.20 
Stable angina 1066  (39.3) 325 (43.8) 125 (41.4) 0.08 
Unstable angina 191 (7.0) 53 (7.1) 27 (8.9) 0.48 
Myocardial infarction 595 (22.0) 213 (28.7) 74 (24.5) <0.001 
PCI or CABG 339 (12.5) 104 (14.0) 27 (8.9) 0.08 
Atrial fibrillation 770 (28.4) 191 (25.7) 69 (22.8) 0.06 
Diabetes mellitus 734 (27.1) 194 (26.1) 83 (27.5) 0.86 
Stroke or transient ischemic attack 249 (9.2) 77 (10.4) 28 (9.3) 0.61 
COPD or asthma 245 (9.0) 73 (9.8) 20 (6.6) 0.26 
QRS e120 milliseconds 0 (0.0) 357 (48.1) 249 (82.5) <0.0001 
QRS duration - milliseconds 86.1 ± 12.1 111.5 ± 26.6 134.5 ±25.0 <0.0001 
MLHFQ Score†    0.004 
Median 42.5 40.0 47.0  
 Q1, Q3 [28.0, 59.5] [27.0, 55.0] [31.0, 60.0]  
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Symptoms and signs - no.(%)     
Ventricular gallop (S3) 203 (7.5) 56 (7.5) 46 (15.3) <0.0001 
Jugular venous distention > 6 cm 212 (7.8) 72 (9.7) 27 (9.0) 0.23  
Lungs    0.69  
Basilar rales 664 (24.5) 182 (24.5) 82 (27.2)   
Diffuse rales 78 (2.9) 26 (3.5) 12 (4.0)   
Wheeze 61 (2.3) 21 (2.8) 7 (2.3)   
Hepatomegaly 482 (17.8) 155 (20.9) 72 (23.9) 0.01  
Peripheral oedema    0.05  
None 1250 (46.1) 301 (40.6) 134 (44.5)   
Trace 856 (31.6) 242  (32.6) 88 (29.2)   
1+ to 2+ 557 (20.6) 179 (24.1) 71 (23.6)   
3+ to 4+ 46 (1.7) 20 (2.7) 8 (2.7)   
Medication - no.(%) 
    
Diuretic 2241 (82.8) 625 (84.2) 265 (87.7) 0.07 
Loop 1387 (51.2) 381 (51.3) 164 (54.3) 0.60 
Thiazide 1037 (38.3) 320 (43.1) 118 (39.1) 0.06 
Spironolactone 400 (14.8) 109 (14.7) 55 (18.2) 0.27 
ACE inhibitor 680 (25.1) 190 (25.6) 85 (28.1) 0.52 
Beta blocker 1641 (60.6) 437 (58.9) 159 (52.6) 0.02 
Calcium channel blocker 1118 (41.3) 286 (38.5) 99 (32.8) 0.01 
Digitalis 364 (13.4) 92 (12.4) 34 (11.3) 0.47 
Antiarrhythmic drug 220 (8.1) 67 (9.0) 26 (8.6) 0.72 
Aspirin 1500 (55.4) 419 (56.5) 174 (57.6) 0.70 
Antiplatelet 1590 (58.7) 458 (61.7) 188 (62.3) 0.21 
Antithrombotic 493 (18.2) 116 (15.6) 47 (15.6) 0.17 
Lipid-lowering agent 838 (31.0) 210 (28.3) 99 (32.8) 0.26 
Laboratory measurements 
    
Hemoglobin - g/dl 14.0 ± 1.5 14.2 ± 1.5 13.9 ± 1.4 0.001 
Potassium - mmol/l 4.5 ± 0.5 4.4 ± 0.5 4.5 ± 0.5 0.86 
Creatinine - mg/dl 0.98 ± 0.31 1.03 ± 0.33 0.99 ± 0.33 0.002 
eGFR - ml/min/1.73 m2 73.3 ± 22.2 72.3 ± 22.6 73.3 ± 22.8 0.59 
eGFR <60 ml/min/1.73 m2 -no.(%) 767 (29.0) 225 (31.0) 95 (31.6) 0.42 
Neutrophil -10^3 cells/ul 4.5 ± 1.8 4.5 ± 1.6 4.5 ±1.5 0.78 
NT-proBNP - pg/ml 
   
0.003 
Median 309.0 331.5 427.0 
 
 Q1,Q3 [125.0, 878.0] [130.5, 904.0] [169.0, 1111.0]  
BBB, bundle branch block; LBBB, left bundle branch block; NYHA, New York heart association; PCI, percutaneous coronary 
intervention; CABG, coronary artery bypass graft; ICD, implantable cardioverter defibrillator; COPD, chronic obstructive 
pulmonary disease; MLHFQ , Minnesota Living with Heart Failure Questionnaire; ACE, angiotensin converting enzyme; eGFR, 
estimated glomerular filtration rate; NT-pro BNP, N-terminal pro-B type natriuretic peptide. 
† Possible scores range from 0 to 105, with lower scores indicating a better quality of life. 
29 
 
 
Table 2.  Endpoints according to QRS interval and QRS morphology category 
 
 
Endpoints 
 
Event no. (%) 
Rate 
(Per 100 patient years) 
Hazard ratio p value Adjusted† 
hazard ratio 
p value 
 
CV death or HF hospitalisation 
     
 
QRS interval, msec 
 
<120 
 
721 (22.9) 
 
6.0 (5.6-6.5) 
 
1.00 
  
1.00 
 
 
e120 
 
200 (33.0) 
 
9.3 (8.1-10.7) 
 
1.54 (1.32-1.80) 
 
<0.001 
 
1.32 (1.11-1.57) 
 
0.002 
 
QRS morphology category 
 
Normal 
 
616 (22.8) 
 
6.0 (5.5-6.5) 
 
1.00 
  
1.00 
 
 
Non-LBBB 
 
210 (28.3) 
 
7.7 (6.7-8.8) 
 
1.28 (1.10-1.50) 
 
0.002 
 
1.19 (1.00-1.42) 
 
0.046 
 
LBBB 
 
94 (31.1) 
 
8.7 (7.1-10.6) 
 
1.44 (1.16-1.78) 
 
0.001 
 
1.31 (1.03-1.66) 
 
0.026 
 
HF hospitalisation 
 
QRS interval, msec 
 
<120 
 
449 (14.3) 
 
3.7 (3.4-4.1) 
 
1.00 
  
1.00 
 
 
e120 
 
117 (19.3) 
 
5.5 (4.6-6.6) 
 
1.44 (1.17-1.76) 
 
0.001 
 
1.24 (0.98-1.55) 
 
0.069 
 
QRS morphology category 
 
Normal 
 
381 (14.1) 
 
3.7 (3.3-4.1) 
 
1.00 
 
 
 
1.00 
 
 
Non-LBBB 
 
127 (17.1) 
 
4.7 (3.9-5.5) 
 
1.25 (1.02-1.53) 
 
0.029 
 
1.14 (0.91-1.43) 
 
0.267 
 
LBBB 
 
58 (19.2) 
 
5.4 (4.1-6.9) 
 
1.42 (1.08-1.88) 
 
0.012 
 
1.31 (0.96-1.77) 
 
0.085 
 
CV death 
 
QRS interval, msec 
 
<120 
 
416 (13.2) 
 
3.2 (2.9-3.5) 
 
1.00 
  
1.00 
 
 
e120 
 
128 (21.1) 
 
5.4 (4.5-6.4) 
 
1.68 (1.38-2.04) 
 
<0.001 
 
1.38 (1.11-1.72) 
 
0.004 
 
QRS morphology category 
 
Normal 
 
354 (13.1) 
 
3.2 (2.9-3.5) 
 
1.00 
  
1.00 
 
 
Non-LBBB 
 
127 (17.1) 
 
4.2 (3.6-5.0) 
 
1.33 (1.09-1.63) 
 
0.006 
 
1.26 (1.00-1.57) 
 
0.047 
 
LBBB 
 
63 (20.9) 
 
5.3 (4.1-6.7) 
 
1.66 (1.27-2.17) 
 
<0.001 
 
1.44 (1.08-1.93) 
 
0.012 
 
Sudden death 
 
QRS interval, msec 
 
<120 
 
153 (4.9) 
 
1.2 (1.0-1.4) 
 
1.00 
  
1.00 
 
 
e120 
 
53 (8.8) 
 
2.2 (1.7-2.9) 
 
1.89 (1.38-2.58) 
 
<0.001 
 
1.43 (1.01-2.02) 
 
0.046 
 
QRS morphology category 
 
Normal 
 
129 (4.8) 
 
1.2 (1.0-1.4) 
 
1.00 
  
1.00 
 
 
Non-LBBB 
 
48 (6.5) 
 
1.6 (1.2-2.1) 
 
1.38 (0.99-1.93) 
 
0.055 
 
1.19 (0.82-1.72) 
 
0.360 
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LBBB 29 (9.6) 2.4 (1.7-3.5) 2.09 (1.40-3.13) <0.001 1.82 (1.18-2.80) 0.006 
 
Pump failure death 
 
QRS interval, msec 
 
<120 
 
78 (2.5) 
 
0.6 (0.5-0.8) 
 
1.00 
  
1.00 
 
 
e120 
 
27 (4.5) 
 
1.1 (0.8-1.7) 
 
1.89 (1.22-2.92) 
 
0.004 
 
1.56 (0.95-2.54) 
 
0.78 
 
QRS morphology category 
 
Normal 
 
62 (2.3) 
 
0.6 (0.4-0.7) 
 
1.00 
  
1.00 
 
 
Non-LBBB 
 
27 (3.6) 
 
0.9 (0.6-1.3) 
 
1.62 (1.03-2.55) 
 
0.037 
 
1.46 (0.87-2.46) 
 
0.155 
 
LBBB 
 
16 (5.3) 
 
1.3 (0.8-2.2) 
 
2.41 (1.39-4.17) 
 
0.002 
 
2.23 (1.24-4.01) 
 
0.007 
 
All cause death 
 
QRS interval, msec 
 
<120 
 
618 (19.6) 
 
4.8 (4.4-5.2) 
 
1.00 
  
1.00 
 
 
e120 
 
162 (26.7) 
 
6.8 (5.8-8.0) 
 
1.43 (1.20-1.70) 
 
<0.001 
 
1.20 (0.99-1.45) 
 
0.06 
 
QRS morphology category 
 
Normal 
 
532 (19.6) 
 
4.8 (4.4-5.2) 
 
1.00 
  
1.00 
 
 
Non-LBBB 
 
172 (23.2) 
 
5.7 (4.9-6.7) 
 
1.20 (1.01-1.43) 
 
0.036 
 
1.15 (0.95-1.39) 
 
0.143 
 
LBBB 
 
76 (25.2) 
 
6.4 (5.1-8.0) 
 
1.33 (1.05-1.69) 
 
0.019 
 
1.15 (0.88-1.49) 
 
0.303 
† Adjusted for age, left ventricular ejection fraction, heart rate, ischemic aetiology, diabetes mellitus, myocardial infarction, 
hospitalization for heart failure in the past 6 months, history of chronic obstructive pulmonary disease or asthma, neutrophils, 
estimated glomerular filtration rate, and N-terminal pro-B type natriuretic peptide. 3091 patients without missing data were included 
in the adjusted model. CV, cardiovascular; HF, heart failure; BBB, bundle branch block; LBBB, left bundle branch block.  
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Figure 1:  Cardiovascular death or hospitalization for HF according to QRS duration.   
(A) QRS <120ms; (B) QRS ≥120ms 
QRS duration (msec) 
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Figure 2:  Cardiovascular death or hospitalization for HF according to QRS morphology.   
(A)  Normal morphology; (B) Non-LBBB morphology (RBBB/IVCD); (C) LBBB morphology 
QRS morphology 
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Figure 1. Kaplan‐Meier curve of the composite outcome according to 
QRS interval (130 msec as the cut‐off)
Figure 2. Kaplan‐Meier curve of HF hospitalization according to 
QRS interval (130 msec as the cut‐off)
Figure 3. Kaplan‐Meier curve of CV death according to QRS interval 
(130 msec as the cut‐off)
Figure 4. Kaplan‐Meier curve of all‐cause death according to QRS interval 
(130 msec as the cut‐off)
Figure 5. Kaplan‐Meier curve of the composite outcome according to 
QRS interval (3 subgruops)
Figure 6. Kaplan‐Meier curve of HF hospitalization according to 
QRS interval (3 subgruops)
Figure 7. Kaplan‐Meier curve of CV death according to QRS interval (3 subgruops)
Figure 8. Kaplan‐Meier curve of all‐cause death according to QRS interval 
(3 subgruops)
Figure 9. Kaplan‐Meier curve of the composite outcome according to 
QRS morphology category (4 subgroups)
Figure 10. Kaplan‐Meier curve of HF hospitalization according to 
QRS morphology category (4 subgroups)
Figure 11. Kaplan‐Meier curve of CV death according to QRS morphology category (4 
subgroups)
Figure 12. Kaplan‐Meier curve of all‐cause death according to QRS morphology 
category (4 subgroups)
